deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT03383692

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors

Sponsor: AstraZeneca

Conditions Neoplasm Metastasis
Interventions DS-8201a Itraconazole Ritonavir
Updated 21 times since 2018 Last updated: Dec 7, 2023 Started: Jan 12, 2018 Primary completion: Sep 26, 2018 Completion: Sep 11, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Neoplasm Metastasis, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 21 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Aug 2020 · 12 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~May 2023 · 13 months · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jan 2024 — Mar 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 16 earlier versions

  1. Oct 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

  2. May 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Aug 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  8. May 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  11. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  12. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  13. Sep 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  14. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  15. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  16. Jan 2018 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Daiichi Sankyo Co., Ltd.
Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations